BioNeutra Global Corporation
BGACF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $2 | $3 |
| % Growth | 15.1% | 7.8% | -9% | – |
| Cost of Goods Sold | $2 | $2 | $3 | $1 |
| Gross Profit | $1 | $1 | -$0 | $2 |
| % Margin | 27.6% | 30.9% | -1.9% | 61.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $2 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $2 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | $1 |
| % Margin | -9.2% | -32.4% | -26.6% | 54% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | $1 |
| % Margin | -13.5% | -28.6% | -33.9% | 51.5% |
| EPS | -0.01 | -0.02 | -0.018 | 0.03 |
| % Growth | 50% | -11.7% | -159.7% | – |
| EPS Diluted | -0.01 | -0.016 | -0.018 | 0.03 |
| Weighted Avg Shares Out | 41 | 46 | 46 | 46 |
| Weighted Avg Shares Out Dil | 46 | 46 | 46 | 46 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $2 |
| % Margin | -5.3% | -13% | -16.5% | 69.4% |